Development of new pyrrolopyrimidine-based inhibitors of Janus kinase 3 (JAK3)

被引：49

作者：

Clark, Michael P.

George, Kelly M.

Bookland, Roger G.

Chen, Jack

Laughlin, Steven K.

Thakur, Kumar D.

Lee, Wenlin

Davis, Jan R.

Cabrera, Ed J.

Brugel, Todd A.

VanRens, John C.

Laufersweiler, Matthew J.

Maier, Jennifer A.

Sabat, Mark P.

Golebiowski, Adam

Easwaran, Vijay

Webster, Mark E.

De, Biswanath

Zhang, George

机构：

[1] Procter & Gamble Pharmaceut, Hlth Care Res Ctr, Mason, OH 45040 USA

[2] Metastatix Inc, Tucker, GA 30084 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2007年 / 17卷 / 05期

关键词：

JAK3; Janus kinase; tyrosine kinases; cytokines; pyrrolopyrimidine;

D O I：

10.1016/j.bmcl.2006.12.018

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A new class of bicyclic pyrrolopyrimidine-based Janus kinase 3 (JAK-3) inhibitors are described. Many of these inhibitors showed low nanomolar activity against JAK-3. (c) 2006 Elsevier Ltd. All rights reserved.

引用

页码：1250 / 1253

页数：4

共 7 条

[1] Mapping the kinase domain of Janus Kinase 3 [J].

Adams, C ;

Aldous, DJ ;

Amendola, S ;

Bamborough, P ;

Bright, C ;

Crowe, S ;

Eastwood, P ;

Fenton, G ;

Foster, M ;

Harrison, TKP ;

King, S ;

Lai, J ;

Lawrence, C ;

Letallec, JP ;

McCarthy, C ;

Moorcroft, N ;

Page, K ;

Rao, S ;

Redford, J ;

Sadiq, S ;

Smith, K ;

Souness, JE ;

Thurairatnam, S ;

Vine, M ;

Wyman, B .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (18) :3105-3110

[2] Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor [J].

Changelian, PS ;

Flanagan, ME ;

Ball, DJ ;

Kent, CR ;

Magnuson, KS ;

Martin, WH ;

Rizzuti, BJ ;

Sawyer, PS ;

Perry, BD ;

Brissette, WH ;

McCurdy, SP ;

Kudlacz, EM ;

Conklyn, MJ ;

Elliott, EA ;

Koslov, ER ;

Fisher, MB ;

Strelevitz, TJ ;

Yoon, K ;

Whipple, DA ;

Sun, JM ;

Munchhof, MJ ;

Doty, JL ;

Casavant, JM ;

Blumenkopf, TA ;

Hines, M ;

Brown, MF ;

Lillie, BM ;

Subramanyam, C ;

Shang-Poa, C ;

Milici, AJ ;

Beckius, GE ;

Moyer, JD ;

Su, CY ;

Woodworth, TG ;

Gaweco, AS ;

Beals, CR ;

Littman, BH ;

Fisher, DA ;

Smith, JF ;

Zagouras, P ;

Magna, HA ;

Saltarelli, MJ ;

Johnson, KS ;

Nelms, LF ;

Des Etages, SG ;

Hayes, LS ;

Kawabata, TT ;

Finco-Kent, D ;

Baker, DL ;

Larson, M .

SCIENCE, 2003, 302 (5646) :875-878

[3] Development of pyrimidine-based inhibitors of Janus tyrosine kinase 3 [J].

Chen, Jack J. ;

Thakur, Kumar D. ;

Clark, Michael P. ;

Laughlin, Steven K. ;

George, Kelly M. ;

Bookland, Roger G. ;

Davis, Jan R. ;

Cabrera, Edward J. ;

Easwaran, Vijay ;

De, Biswanath ;

Zhang, Y. George .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (21) :5633-5638

[4] Of genes and phenotypes:: the immunological and molecular spectrum of combined immune deficiency.: Defects of the γc-JAK3 signaling pathway as a model [J].

Notarangelo, LD ;

Giliani, S ;

Mazza, C ;

Mella, P ;

Savoldi, G ;

Rodriguez-Pérez, C ;

Mazzolari, E ;

Fiorini, M ;

Duse, M ;

Plebani, A ;

Ugazio, AG ;

Vihinen, M ;

Candotti, F ;

Schumacher, RF .

IMMUNOLOGICAL REVIEWS, 2000, 178 :39-48

[5] A new modality for immunosuppression: Targeting the JAK/STAT pathway [J].

O'Shea, JJ ;

Pesu, M ;

Borie, DC ;

Changelian, PS .

NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (07) :555-564

[6] The role of Jak3 in lymphoid development, activation, and signaling [J].

Thomis, DC ;

Berg, LJ .

CURRENT OPINION IN IMMUNOLOGY, 1997, 9 (04) :541-547

[7] Photochemical preparation of a pyridone containing tetracycle: A Jak protein kinase inhibitor [J].

Thompson, JE ;

Cubbon, RM ;

Cummings, RT ;

Wicker, LS ;

Frankshun, R ;

Cunningham, BR ;

Cameron, PM ;

Meinke, PT ;

Liverton, N ;

Weng, YM ;

DeMartino, JA .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (08) :1219-1223

← 1 →